Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MKL1
REST API REST API
Homo sapiens
MKL1 is differentially expressed in 302 experiments: 139 organism parts: bone marrow, kidney, ... (137 more);, 236 disease states: normal, acute myeloid leukemia, ... (234 more);, 106 cell types 387 cell lines 49 compound treatments and 84 other conditions.
Synonyms KIAA1438, MAL, MRTF-A, BSAC
Orthologs ENSCING00000009545 (Ciona intestinalis)   Mkl1 (Mus musculus)   Mkl1 (Rattus norvegicus)   MKL1 (1 of 2) (Danio rerio)   MKL1 (Bos taurus)   MKL1 (Gallus gallus)   MKL1 (2 of 2) (Danio rerio)   Mrtf (Drosophila melanogaster)   mkl1 (Xenopus laevis)   MKL1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, actin monomer binding, cytoplasm, nucleic acid binding, anti-apoptosis, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, positive regulation of transcription, DNA-dependent, actin binding, leucine zipper domain binding, smooth muscle cell differentiation
InterPro Term RPEL_repeat, SAP_DNA-bd
UniProt Accession Q29R68, Q969V6, B0QY84, B0QY83, B0QY74, E7ER32, E9PCL0
Search EB-eye ENSG00000196588
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
DU145
2
E-GEOD-17482, E-GEOD-20089
MCF-7
2
E-GEOD-20081, E-GEOD-5823
MOLT4
2
E-MTAB-37, E-MTAB-62
primary culture
2
E-GEOD-1657, E-GEOD-2450
CHL1
1
E-MTAB-37
381 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (52 experiments)

Factor Value U/D Experiments
CD34+
2
E-TABM-145, E-AFMX-5
macrophage
2
E-GEOD-22373, E-GEOD-5099
CD14+ monocyte
3
2
E-AFMX-5, E-TABM-145
testis - leydig cell
1
E-TABM-145
CD34+Thy+ hematopoietic stem cell
1
E-GEOD-96
primary fibroblast
1
E-MEXP-66
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (63 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
myeloma
2
E-MTAB-372, E-MTAB-37
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
colon carcinoma
2
E-MTAB-37, E-MTAB-62
lymphoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
230 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-TABM-782, ... (31 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-5339
glutamine
2
E-MEXP-941, E-MEXP-1335
Cxcl12
1
E-GEOD-7307
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
oligomycin
1
E-GEOD-5258
heregulin
1
E-GEOD-6462
43 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2191, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-17476, E-MEXP-421, E-TABM-43, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.327 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM